Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

NCT01977755 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

591

Enrollment

INDUSTRY

Sponsor class

Conditions

Focus of Study is STEMI

Interventions

DRUG: danegaptide
DRUG: Placebo

Sponsor

Zealand Pharma